Patient Involvement in medicines development R&D: making a difference A few Parkinsons UK volunteers and staff were recently privileged to attend this EUPATI workshop hosted at the GSK HQ in London, and came away enthused and brimming with plenty of new ideas, contacts and resources. Anyone involved in PPI (Patient and Public Involvement) for medical research and development ought to be aware of this valuable work and free Creative Commons resources.
Cannabis-derived medical products have been in the news lately, after two boys with epilepsy had their treatments taken away from them. On the back of the spike in public profile, the government has moved to legalise such products in cases of ‘exceptional clinical need’. In turn, Parkinson’s UK has moved to support this shift – comparing the re-classification to how morphine is used in medicine. The statement in response also made reference to the potential benefits of cannabidiol for Parkinson’s symptoms such as pain and sleep problems. Parkinson’s UK head of policy and campaigning Laura Cockram said: “We want to seek the views of people with Parkinson’s to guide…